The Ends of Lecirelin on the Destruction of Ovarian Cancer Cells
International Pharmacy Acta,
Vol. 7 No. 1 (2024),
24 July 2024
,
Page e5: 1-8
https://doi.org/10.22037/ipa.v7i1.46123
Abstract
As a gynecological cancer, ovarian cancer has the highest lethality among females on the globe. Evidence shows that the GnRH agonists and antagonists dramatically inhibit the growth of most cancer cell lines expressing the GnRH receptor. The current research focuses on the effectiveness of three novel GnRH analogs showing anticancer activities on the cell lines of ovarian cancer. The present investigation synthesized Lecirelin in the solid phase and changed the peptide chain’s C-terminal. Two ovarian cancer cell lines were examined for the impacts of the purified peptides. The hydrazide derivative with an approximate concentration of 30 mg/mL (lC50~30) can kill more than half of the ovarian cancer cells, while the Lecirline needs twice more active ingredient to kill this amount of the cells (lC50~47, p = 0.001). Lecirelin and its hydrazide derivative have anticancer activity against ovarian cancer cells, and this GnRH analog may be considered a promising candidate for further studies.
- Lecirelin
- Ovarian cancer
- Gonadotropin-releasing hormone (GnRH)
- Peptide
- Hydrazide
- MTT
How to Cite
References
Guryanov I, Orlandin A, Viola A, Biondi B, Badocco D, Formaggio F. et al. Overcoming Chemical Challenges in the Solid-Phase Synthesis of High-Purity GnRH Antagonist Degarelix. Part 1. Org Process Res Dev. 2019;23:2746−53.
Minko T, Rodriguez-Rodriguez L, Pozharov V. Nanotechnology approaches for personalized treatment of multidrug resistant cancers. Adv Drug Deliver Rev. 2013;65:1880–95.
Mezo G, Manea M, Szabo I, Vincze B, Kovacs M. New Derivatives of GnRH as Potential Anticancer Therapeutic Agents. Current Med Chem. 2008;15:2366-79.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. 2018;68(6):394–424.
Gründker C, Emons G. Role of Gonadotropin-Releasing Hormone (GnRH) in Ovarian Cancer. Cells 2021;10(2):437.
Cho KR, Shih IM. Ovarian Cancer. Annu Rev Pathol Mech Dis. 2009;4:287–313.
Baba Y, Matsuo H, Schally AV. Structure of the porcine LH- and FSH-releasing hormone. II. Confirmation ofthe proposed structure by conventional sequential analyses. Biochem Biophys Res Commun. 1971;44(2):459–63.
Matsuo H, Baba Y, Nair RM, Arimura A, Schally AV. Structure of the porcine LH- and FSH-releasing hormone I. The proposed amino acid sequence. Biochem Biophys Res Commun. 1971; 43(6):1334–39.
Schally AV, Arimura A, Baba Y, Nair RMG, Matsuo H, Redding TW, et al. Isolation and properties ofthe FSH and LH-releasing hormone. Biochem Biophys Res Commun. 1971;43(2):393–99.
Conn PM, Crowley Jr WF. Gonadotropin-releasing hormone and its analogs. Annu Rev Med. 1994;45:391–405.
Mirzaei Saleh-Abady M, Alizadeh A, Shamsipour F, Naderi-Manesh H. The Anticancer Activity Compared Between Triptorelin and a New Gonadotropin Releasing Hormone Analogue. Avicenna J Med Biotech. 2009;1(2): 105-10.
Emons G, Weiss S, Ortmann O, Grundker C, Schulz KD. LHRH might act as a negative autocrine regulator of proliferation of human ovarian cancer. Eur J Endocrinol. 2000;142(6):665-70.
Xiong S, Mhawech-Fauceglia P, Tsao-Wei D, Roman L, Gaur RK, Epstein AL et al. Expression of the luteinzing hormone receptor (LHR) in ovarian cancer. BMC Cancer. 2019;19(11):1114.
Emons G, Ortmann O, Becker M, Irmer G, Springer B, Laun R, et al. High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer res. 1993;53(22):5439-46.
Sadek H, Ghaly A, Varamini P. New drug delivery strategies targeting the GnRH receptor in breast and other cancers. Endocr Relate Cancer. 2021;28(11):R251–R269.
Zhng Y, Katsaros D, Shan SJ, de la Longrais IR, Porpiglia M, Scorilas A, et al. A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy. Clin Cancer Res. 2007;13(23):6984-92.
Engel JB, Schally AV. Drug insight:clinical use of agonists and antagonists of lutnizing-hormon-releasing hormone. Nat Clin Pract Endocrinol Metab. 2007;3(2):157-67.
Verschraegen CF, Westphalen S, Hu W. Loyer E, Kudelka A, Völker P, et al. Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2003;90(3):552-59.
Garrido MP, Hernandez A, Vega M, Araya E, Romero C. Conventional and new proposals of GnRH therapy for ovarian, breast, and prostatic cancers. Front Endocrinol (Lausanne). 2023; 14:1143261.
Söderhäll JA, Polymeropoulos EE, Paulini K, Günther E, Kühne R. Antagonist and agonist binding models of the human gonadotropin-releasing hormone receptor. Biochem Biophys Res Commun. 2005;333(2):568–82.
Moretti RM, Montagnani Marelli M, Van Groeninghen JC, Limonta P. Locally expressed LHRH receptors mediate the oncostatic and antimetastatic activity of LHRH agonists on melanoma cells. J Clin Endocrinol Metab. 2002;87(8):3791–97.
Marelli MM, Moretti RM, Mai S, Müller O, Van Groeninghen JC, Limonta P. Novel insights into GnRH receptor activity: role in the control of human glioblastoma cell proliferation. Oncol Rep. 2009;21(5):1277–82.
Taratula O, Garbuzenko OB, Chen AM, Minko T. Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. J Drug Target. 2011;19(10):900–14.
Friess H, Büchler M, Kiesel L, Krüger M, Beger HG. LH-RH receptors in the human pancreas. Basis for anti hormonal treatment in ductal carcinoma of the pancreas. Int J Pancreatol, 1991;10(2):151–159.
Gründker C, Günthert AR, Westphalen S, Emons G. Biology of the gonadotropin-releasing hormone system in gynecological cancers. Eur J Endocrinol. 2002;146(1):1–14.
Beck-Fruchter R, Weiss A, Shaley E. GnRH agonist therapy as ovarian protectants in female patients undergoing chemotherapy: a review of the clinical data. Hum Reprod Update, 2008;14(6):553-61.
Valsamakis G, Valtetsiotis K, Charmandari E, Lambrinoudaki I, Vlahos NF. GnRH analouges as a co-treatment to therapy in woman of reproduvtive age with cancer and Fertility preservation. Int J Mol Sci. 2022;23(4):2287.
Li H, Lin Y, Wang Y, Zhao X, Qi X. Hormone therapy for ovarian cancer:Emphasis on mechanisms and applications (Review). Oncol Rep. 2021;46(4):223.
Perry CM, Brogden RN. Goserelin: a review of its pharmacodynamics and pharmacokinetic properties, and therapeuticuse in benign gynaecological disorders. Drugs. 1996;51(2):319-46.
Cockshott ID. Clinical pharmacokinetics of Goserelin. Clin Pharm. 2000;39(1):27-48.
Zhang N, Qiu J, Zheng T, Zhang X, Hua K, Zhang Y. Goserelin promotes the apoptosis of epithelial ovarian cancer cells by upregulating forkhead box O1 through the PI3K/AKT signaling pathway. Oncol Rep. 2018;39(3):1034-42.
Swayzer DV, Gerriets V. Leuprolide:Statpearls:Treasure Island, FL, USA. 2022.
- Abstract Viewed: 119 times
- IPA-2024 Vol7i1-e5 Downloaded: 126 times